Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus
Authors:
Open Access
- 28 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 31 (1) , 56
Abstract
Background: Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistant to standard therapies. HDIT101, a humanized IgG targeting HSV-1/2 gB was previously investigated in phase 2 clinical trials. The aim of this study was to develop a next-generation therapy by combining different antiviral monoclonal antibodies. Methods: A lymph-node derived phage display library (LYNDAL) was screened against recombinant gB from Herpes simplex virus (HSV) -1 and HDIT102 scFv was selected for its binding characteristics using bio-layer interferometry. HDIT102 was further developed as fully human IgG and tested alone or in combination with HDIT101, a clinically tested humanized anti-HSV IgG, in vitro and in vivo. T-cell stimulating activities by antigen-presenting cells treated with IgG-HSV immune complexes were analyzed using primary human cells. To determine the epitopes, the cryo-EM structures of HDIT101 or HDIT102 Fab bound to HSV-1F as well as HSV-2G gB protein were solved at resolutions < 3.5 Å. Results: HDIT102 Fab showed strong binding to HSV-1F gB with Kd of 8.95 × 10–11 M and to HSV-2G gB with Kd of 3.29 × 10–11 M. Neutralization of cell-free virus and inhibition of cell-to-cell spread were comparable between HDIT101 and HDIT102. Both antibodies induced internalization of gB from the cell surface into acidic endosomes by binding distinct epitopes in domain I of gB and compete for binding. CryoEM analyses revealed the ability to form heterogenic immune complexes consisting of two HDIT102 and one HDIT101 Fab bound to one gB trimeric molecule. Both antibodies mediated antibody-dependent phagocytosis by antigen presenting cells which stimulated autologous T-cell activation. In vivo, the combination of HDIT101 and HDIT102 demonstrated synergistic effects on survival and clinical outcome in immunocompetent BALB/cOlaHsd mice. Conclusion: This biochemical and immunological study showcases the potential of an effective combination therapy with two monoclonal anti-gB IgGs for the treatment of HSV-1/2 induced disease conditions.Keywords
Funding Information
- Heidelberg ImmunoTherapeutics GmbH
This publication has 53 references indexed in Scilit:
- Not So Different After All: A Comparison of Methods for Detecting Amino Acid Sites Under SelectionMolecular Biology and Evolution, 2005
- TM-align: a protein structure alignment algorithm based on the TM-scoreNucleic Acids Research, 2005
- Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir EraPediatrics, 2001
- EMBOSS: The European Molecular Biology Open Software SuiteTrends in Genetics, 2000
- Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 InfectionJAMA, 1999
- Topically Applied Human Recombinant Monoclonal IgG1Antibody and Its Fab and F(ab′)2Fragments Protect Mice from Vaginal Transmission of HSV-2Virology, 1996
- Protection of Nude Mice by Passive Immunization with a Type-Common Human Recombinant Monoclonal Antibody against HSVVirology, 1996
- Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.Journal of Clinical Investigation, 1990
- Neonatal Antibody-Dependent Cellular Cytotoxic Antibody Levels Are Associated with the Clinical Presentation of Neonatal Herpes Simplex Virus InfectionThe Journal of Infectious Diseases, 1989
- Glycoproteins of herpes simplex virus type 2 as defined by monoclonal antibodiesJournal of Virology, 1982